Sign In
Buy SLS
$11.81
+0.590 (+5.26%)
At Close: Aug 04, 2026
SELLAS Life Sciences to Present at the JMP Securities Life Sciences Conference on June 15th
12:30pm, Thursday, 02'nd Jun 2022 GlobeNewswire Inc.
NEW YORK, June 02, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad r
SELLAS Life Sciences to Present at the JMP Securities Life Sciences Conference on June 15th
08:30am, Thursday, 02'nd Jun 2022
NEW YORK, June 02, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad ran
Solaris Receives $30 Million from Warrant Exercises; Fully Funded Through to Mid-2023
11:00am, Friday, 13'th May 2022 GlobeNewswire Inc.
VANCOUVER, B.C., May 13, 2022 (GLOBE NEWSWIRE) -- Solaris Resources Inc. (TSX: SLS; OTCQB: SLSSF) (“Solaris” or the “Company”) is pleased to announce that the Company has received approximat
SELLAS Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update
08:12pm, Thursday, 12'th May 2022 GlobeNewswire Inc.
- Enhanced Pipeline with New Asset, GFH009, an In-licensed Next-Generation, Highly Selective CDK9 Inhibitor -
VANCOUVER, British Columbia, April 18, 2022 (GLOBE NEWSWIRE) -- Solaris Resources Inc. (TSX: SLS; OTCQB: SLSSF) (“Solaris” or the “Company”) is pleased to report an updated mineral resource
Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022
02:03pm, Thursday, 14'th Apr 2022 Benzinga
Upgrades
For United Parcel Service Inc (NYSE:UPS), Loop Capital upgraded the previous rating of Hold to Buy. For the fourth quarter, United Parcel Service had an EPS of $3.59, compared to year-ago qua
SELLAS Life Sciences’ Newly Licensed GFH009 Asset Shows Significant Anti-Leukemic Effect in Acute Myeloid Leukemia Patients Relapsed/Refractory to Venetoclax in Ongoing Phase 1 Study
12:15pm, Monday, 11'th Apr 2022 GlobeNewswire Inc.
- Fifth Dose Level Cohort of GFH009, a Highly Selective CDK9 Inhibitor, Initiated -
Solaris Reports 616m of 0.6% CuEq in Additional Drilling at Warintza East, Establishes Continuity of Mineralization with Warintza Central
11:30am, Monday, 11'th Apr 2022 GlobeNewswire Inc.
VANCOUVER, British Columbia, April 11, 2022 (GLOBE NEWSWIRE) -- Solaris Resources Inc. (TSX: SLS; OTCQB: SLSSF) (“Solaris” or “the Company”) is pleased to report assay results from a series
SELLAS Life Sciences Announces Achievement of Development Milestone for Approval of IND for Galinpepimut-S in China
11:00am, Wednesday, 06'th Apr 2022 GlobeNewswire Inc.
SELLAS to Receive $1 Million Milestone Payment in Second Quarter 2022 SELLAS to Receive $1 Million Milestone Payment in Second Quarter 2022
SELLAS Life Sciences Provides Business Update and First Quarter 2022 Highlights
08:51pm, Tuesday, 05'th Apr 2022 GlobeNewswire Inc.
– In-licensed Next-Generation, Highly Selective CDK9 Inhibitor –
Solaris Adds to Near Surface, High-Grade Northeast and Southeast Extensions, Priorities for Further Growth Beyond Mineral Resource
11:00am, Monday, 04'th Apr 2022 GlobeNewswire Inc.
VANCOUVER, British Columbia, April 04, 2022 (GLOBE NEWSWIRE) -- Solaris Resources Inc. (TSX: SLS; OTCQB: SLSSF) (“Solaris” or “the Company”) is pleased to report assay results from a series
SELLAS Life Sciences Stock Plunges After $25M Capital Raise Via Equity, In-Licenses Cancer-Focused CDK9 Inhibitor
08:58am, Friday, 01'st Apr 2022
GenFleet Therapeutics has granted GFH009 rights to SELLAS Life Sciences Group Inc (NASDAQ: SLS) across all therapeutic and diagnostic uses worldwide outside of Greater China (mainland China, Hong
SELLAS Life Sciences Announces Pricing of $25.0 Million Underwritten Public Offering
01:03am, Friday, 01'st Apr 2022 GlobeNewswire Inc.
NEW YORK, March 31, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the develo
SELLAS Life Sciences Announces Proposed Underwritten Public Offering
08:11pm, Thursday, 31'st Mar 2022 GlobeNewswire Inc.
NEW YORK, March 31, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the develo
SELLAS Life Sciences Signs Exclusive License Agreement with GenFleet Therapeutics for Next-Generation, Highly Selective CDK9 Inhibitor
08:08pm, Thursday, 31'st Mar 2022 GlobeNewswire Inc.
- SELLAS In-licenses Worldwide Rights Outside of Greater China for Clinical-Stage Asset -
